arrow
Back
D

David R. Spigel

roche holding usa

97H-index
907Paper Count
7.8WCitation Count
Published Papers 158
Publication Date
Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial
err2025-12-01
err0
PREAI
errZuniga, Richard M.; Vanderwalde, Ari; Schwartzberg, Lee S.; Spigel, David R.; Passler, Luke; Hong, Jason; Howland, Michael; Darbonne, Walter C.; Szado, Tania; Daniel, Davey
errShare
errSave
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up
err2025-11-18
err0
errOAAI
errMarcia Cruz-Correa; Do-Youn Oh; Ken Kato; Josep Tabernero; Yuxian Bai; Jianhua Shi; Keun-Wook Lee; Hidekazu Hirano; David Spigel; Lucjan Wyrwicz; Roberto Pazo Cid; Antonio Cubillo Gracián; Yaling Xu; Tao Sheng; Silu Yang; Rui-Hua Xu; Markus Moehler
errShare
errSave
Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer
err2025-11-10
err0
errOAAI
errMelissa L. Johnson; Shaker R. Dakhil; J. Thaddeus Beck; Ahad Sadiq; Smitha Menon; Ganesh M. Mugundu; Juliann Chmielecki; David R. Spigel
errShare
errSave
Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials
err2025-08-05
err0
PREAI
errRoy S. Herbst; Hen Prizant; Daniel Ruderman; Jake Conway; John Shamshoian; Hartmut Koeppen; Wei Zou; Filippo de Marinis; Giuseppe Giaccone; Jacek Jassem; David R. Spigel; Mark A. Socinski; Martin Reck; Luciana Molinero; Marcus Ballinger; David Shames; Michael Griffin; Limin Yu; Nishant Agrawal; Andrew Beck; Ilan Wapinski; Stephanie Hennek; Jennifer Giltnane; Minu K. Srivastava
errShare
errSave
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
err2025-06-24
err0
errOAAI
errDavid R Spigel; Virginie Westeel; Ian C Anderson; Laurent Greillier; Florian Guisier; Olivier Bylicki; Firas B Badin; Gaelle Rousseau-Bussac; Clotilde Deldycke; Frank Griesinger; Adam Bograd; Wangjian Zhong; Jacques Le Treut; Sylvie Van Hulst; David R Gandara; Martin Reck; Petra Hoffknecht; Matthew A Gubens; John Crowley; Heiko von der Leyen; Gavitt A Woodard; David M Jablons; Johannes R Kratz; Michael J Mann
errShare
errSave
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab
err2025-05-28
err0
errOAAI
errCharles Swanton; Russell W. Madison; Candice Francheska B. Tambaoan; Funda Meric-Bernstam; Christopher J. Sweeney; Razelle Kurzrock; Howard A. Burris III; David R. Spigel; Hanna Tukachinsky; Jason Hughes; Julia Malato; Bongin Yoo; Tania Szado; Cheryl Schwab; Lincoln W. Pasquina; Amaya Gasco; Katja Schulze; Claire F. Friedman
errShare
errSave
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
err2025-03-01
err0
errOAAI
errMoehler, Markus; Oh, Do-Youn; Kato, Ken; Arkenau, Tobias; Tabernero, Josep; Lee, Keun-Wook; Rha, Sun Young; Hirano, Hidekazu; Spigel, David; Yamaguchi, Kensei; Wyrwicz, Lucjan; Disel, Umut; Pazo-Cid, Roberto A.; Fornaro, Lorenzo; Xu, Yaling; Sheng, Tao; Yang, Silu; Kadva, Alysha; Cruz-Correa, Marcia; Xu, Rui-Hua
errShare
errSave
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors
err2024-11-19
err0
errOAAI
errPatel, Manish R.; Falchook, Gerald S.; Wang, Judy S.; Imedio, Esteban Rodrigo; Kumar, Sanjeev; Miah, Kowser; Mugundu, Ganesh M.; Jones, Suzanne F.; Spigel, David R.; Hamilton, Erika P.
errShare
errSave
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial
err2024-11-01
err1
errOAAI
errHamilton, Erika P.; Falchook, Gerald S.; Wang, Judy S.; Fu, Siqing; Oza, Amit M.; Imedio, Esteban Rodrigo; Kumar, Sanjeev; Ottesen, Lone; Mugundu, Ganesh M.; de Bruin, Elza C.; O'Connor, Mark J.; Jones, Suzanne F.; Spigel, David R.; Li, Bob T.
errShare
errSave
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
err2024-10-10
err8
PREAI
errCheng, Ying; Spigel, David R.; Cho, Byoung Chul; Laktionov, Konstantin K.; Fang, Jian; Chen, Yuanbin; Zenke, Yoshitaka; Lee, Ki Hyeong; Wang, Qiming; Navarro, Alejandro; Bernabe, Reyes; Buchmeier, Eva Lotte; Chang, John Wen-Cheng; Shiraishi, Yoshimasa; Goksu, Sema Sezgin; Badzio, Andrzej; Shi, Anhui; Daniel, Davey B.; Hoa, Nguyen Thi Thai; Zemanova, Milada; Mann, Helen; Gowda, Hema; Jiang, Haiyi; Senan, Suresh
errShare
errSave
Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results
err2024-09-01
err0
PREAI
errHendifar, A.; Gong, J.; Spigel, D. R.; Basu-Mallick, A.; Espinosa, A.; Misleh, J. G.; Richards, D.; Boles, J.; Fakih, M.; Paulson, A. S.; Chung, K.; Cohn, A.; Gupta, M.; Johnson, K.; Bechar, N.; Hoffman, K. A.; Spector, S.; Szarek, M.; Wasserman, R.; Rosen, L. S.
errShare
errSave
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
err2024-09-01
err4
PREAI
errCruz-Correa, M.; Oh, D-Y.; Kato, K.; Tabernero, J.; Bai, Y.; Shi, J.; Lee, K-W.; Hirano, H.; Spigel, D. R.; Wyrwicz, L. S.; Pazo Cid, R. A.; Cubillo Gracian, A.; Li, L.; Xu, Y.; Sheng, T.; Yang, S.; Xu, R-H.; Moehler, M.
errShare
errSave
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
err2024-05-28
err10
errOAAI
errQiu, Miao-Zhen; Oh, Do-Youn; Kato, Ken; Arkenau, Tobias; Tabernero, Josep; Correa, Marcia Cruz; Zimina, Anastasia, V; Bai, Yuxian; Shi, Jianhua; Lee, Keun-Wook; Wang, Jufeng; Poddubskaya, Elena; Pan, Hongming; Rha, Sun Young; Zhang, Ruixing; Hirano, Hidekazu; Spigel, David; Yamaguchi, Kensei; Chao, Yee; Wyrwicz, Lucjan; Disel, Umut; Cid, Roberto Pazo; Fornaro, Lorenzo; Evesque, Ludovic; Wang, Hongwei; Xu, Yaling; Li, Jiang; Sheng, Tao; Yang, Silu; Li, Liyun; Moehler, Markus; Xu, Rui-Hua
errShare
errSave
A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in triple negative breast cancer and transcriptionally addicted relapsed or refractory solid tumors
err2024-05-02
err0
PREAI
errMita, Monica; Mita, Alain; Villalona-Calero, Miguel; Federman, Noah; Rasco, Drew; Spigel, David; Luo, Jia; Cote, Gregory; Cutler, Richard; Kumar, Pavan; MacKenzie, Crystal; Lin, Charles; DiMartino, Jorge; Olek, Elizabeth; Van Tine, Brian
errShare
errSave
Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)
err2024-04-05
err1
PREAI
errIzar, Benjamin; Zamarin, Dmitriy; Spigel, David R.; Hoimes, Christopher J.; McDermott, David F.; Sehgal, Kartik; Najjar, Yana G.; Schoenfeld, Adam J.; Garon, Edward B.; Sullivan, Ryan J.; Henick, Brian S.; Leal, Ticiana A.; Hurwitz, Michael E.; McKay, Rana R.; Busby, Natalie; Mehta-Damani, Anita; Azrilevich, Alex; Tran, Tony; Rizvi, Naiyer; Oft, Martin; Spira, Alexander I.
errShare
errSave
A dose escalation and cohort expansion study of the CDK9 inhibitor KB0742 in relapsed, refractory and transcriptionally addicted solid tumors
err2024-04-05
err0
PREAI
errCalero, Miguel Villalona; Agulnik, Mark; Mita, Monica; Mita, Alain; Federman, Noah; Rasco, Drew; Spigel, David; Luo, Jia; Hanna, Glenn; Cote, Gregory; Salkeni, Mohamad A.; Chugh, Rashmi; Ammakkanavar, Natraj R.; Shah, Satish A.; Rao, Amol; Sankhala, Kamalesh Kumar; Cutler, Richard E.; Hood, Tressa; Carvajal, Luis; MacKenzie, Crystal; Lin, Charles; DiMartino, Jorge; Olek, Elizabeth A.; Van Tine, Brian
errShare
errSave
First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data
err2024-04-05
err0
PREAI
errVan Tine, Brian A.; Ahn, Eugene; Redman, Rebecca A.; Barve, Minal A.; Edenfield, William J.; Peguero, Julio; Villaflor, Victoria M.; Rasco, Drew W.; Powell, Steven F.; Mamuye, Admasu T.; Moore, Chris B.; Pelham, Joshua M.; Charoenthongtrakul, Soratree; Spigel, David R.
errShare
errSave
Tumor informed circulating tumor DNA monitoring for early treatment response and survival outcomes on trastuzumab plus pertuzumab
err2024-03-22
err0
PREAI
errKurzrock, Razelle; Childress, Merrida; Li, Wenshu; Muse, Anna; Malato, Julia; Wang, Yong; Liu, Minetta; Aleshin, Alexey; Wang, Richard S.; Thierauf, Julia; Sweeney, Christopher J.; Hainsworth, John; Szado, Tania; Young, Amanda; Schulze, Katja; Spigel, David; Meric-Bernstam, Funda; Swanton, Charles; Burris, Howard A.
errShare
errSave
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
err2024-03-13
err13
errOAAI
errLenz, Heinz-Josef; Parikh, Aparna; Spigel, David R.; Cohn, Allen L.; Yoshino, Takayuki; Kochenderfer, Mark; Elez, Elena; Shao, Spencer H.; Deming, Dustin; Holdridge, Regan; Larson, Timothy; Chen, Eric; Mahipal, Amit; Ucar, Antonio; Cullen, Dana; Baskin-Bey, Edwina; Kang, Tong; Hammell, Amy B.; Yao, Jin; Tabernero, Josep
errShare
errSave
A dose escalation and cohort expansion study of the CDK9 inhibitor KB0742 in relapsed, refractory ovarian cancer and transcriptionally addicted relapsed or refractory solid tumors
err2024-03-04
err0
PREAI
errVillalona-Calero, Miguel; Mita, Monica; Mita, Alain; Federman, Noah; Rasco, Drew; Spigel, David; Luo, Jia; Cote, Gregory M.; Cutler, Richard E.; Kumar, Pavan; MacKenzie, Crystal J.; Lin, Charles; DiMartino, Jorge F.; Olek, Elizabeth A.; Van Tine, Brian
errShare
errSave